SSL International plc (“SSL”) announces that it has exchanged conditional contracts with Langer Inc for the disposal of the US based Silipos business, which consists of gel based products for prosthetic, orthopedic and skin care applications. This is the final transaction in SSL’s medical division disposal programme and completion is expected on 30th September 2004.

Total proceeds are US$15.5 million represented by cash of US$5 million, a vendor loan note of US$7.5 million redeemable on or before March 2006 and a second vendor loan note of US$3 million redeemable on or before December 2009.

Sales of Silipos in the year to 31st March 2004 of £12 million generated a pre-exceptional operating profit of £0.6 million before interest and tax. Based upon current exchange rates, equivalent figures in US dollars are approximately US$ 22 million and US$1.2 million respectively.

For further information, please contact:

SSL International plc
Jan Young, Head of Investor Relations
020 7367 5773

The Maitland Consultancy
William Clutterbuck or Brian Hudspith
020 7379 5151